TheEdgeResearch
Home / Stocks / DTCFF

Defence Therapeutics Inc. (DTCFF)

OTC Healthcare Biotechnology
$0.30 ▲ +1.84%
Market Cap
$22.7M
Sector
Healthcare
Industry
Biotechnology
Beta
1.35
52-Wk Range
0.2533-0.7787
CEO
Sébastien Plouffe
Country
CA
Currency
USD

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vac…

Open full interactive analysis & DCF →